Agios ends development of tebapivat in low-risk MDS following subpar results

May 29, 2026 10:50 AM EDT R&D Agios ends de­vel­op­ment of tebapi­vat in low-risk MDS fol­low­ing sub­par re­sults Ayisha Sharma News Reporter Agios Phar­ma­ceu­ti­cals has said it will stop de­vel­op­ing its rare blood dis­or­der drug for cer­tain pa­tients with myelodys­plas­tic syn­dromes (MDS) due to dis­ap­point­ing Phase 2b … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER